A ruthenium catalyst facilitated the polymerization, or polymer addition. Industrial firms have used this catalyst to make ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...